European stocks traded lower on Monday as the U.S. dollar strengthened after hawkish comments from U.S. Federal Reserve Chair Janet Yellen in a closely watched speech Friday.
Some of the names on the move ahead of the open.
The U.S. Food and Drug Administration issued emergency authorization for a Zika diagnostics test from Swiss drugmaker Roche.
Kevin O'Leary said that companies that are paying out dividends are "hitting it out of the park."
European stocks finished mostly around the flatline after the ECB left its key interest rate unchanged and as investors digested more earnings.
Roche CEO, Severin Schwan explains why the impact of Brexit on the pharmaceutical firm is "rather limited".
Swiss drugmaker Roche on Thursday confirmed its outlook for 2016 and reported sales for the first half of the year ahead of analyst expectations.
Severin Schwan, CEO of Roche, discusses the highlights from the company's earnings results for the first half of 2016.
Shares of BioMarin jumped more than 10 percent in early trading after a report said Roche may be seeking to acquire it.
A broad coalition is urging the U.S. Supreme Court to review the cancellation of a patent on a less risky form of prenatal testing.
European stocks surged by Monday's close, as declining fears of a Brexit vote buoyed global market sentiment, sterling and oil prices.
The rapid increase in Zika virus infections in Puerto Rico could put thousands of pregnant women at risk for potential infection.
CNBC's Meg Tirrell speaks with Daniel O'Day, Roche Holdings CEO of Pharmaceuticals Division, at the ASCO Conference about the company's cancer drug developments and the state of the pharmaceuticals industry.
As the world's largest cancer research conference gets underway, here's how to play the stocks.
European stocks eked out gains on Friday amid a decline in oil prices.
Roche got a big boost on Friday when a clinical trial testing its new blood cancer drug Gazyva proved successful.
Novartis is discussing options with banks for selling its $13.8 billion stake in rival Roche, though a sale is not imminent.
Roche reiterated on Tuesday that it expects to achieve its full-year targets after sales during the first three months of 2016 rose 4 percent.
European markets finished in the red on Thursday, as a slump in health care stocks weighed on investors, despite a recovery in oil.
The U.S. Food and Drug Administration recommended that blood should no longer be collected from regions where the Zika virus is circulating.